ACL — Australian Clinical Labs Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapContrarian

Annual income statement for Australian Clinical Labs, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

	2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	491	647	996	697	696
Cost of Revenue
Gross Profit	404	527	788	571	577
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	443	538	729	635	643
Operating Profit	47.4	109	267	62	52.9
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	30.8	86.7	255	48.3	36.4
Provision for Income Taxes
Net Income After Taxes	41.3	60.4	178	36	24.2
Minority Interest
Net Income Before Extraordinary Items
Net Income	41.3	60.4	178	35.9	23.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	41.3	60.4	178	35.9	23.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.204	0.366	0.905	0.178	0.137
Dividends per Share